Zai Lab Q2 net product revenue $100.1M (+45% YoY); narrows net loss to $80.3M

Zai Lab Ltd

2024-Q2 EPS reported -$0.14 revenue$187,653,000

Net product revenue $100.1M, up 45% YoY (47% at CER); VYVGART contributed $23.2M vs $0.1M YoY.
Net loss $80.3M ($0.82/ADS loss), improved from $120.9M loss ($1.25/ADS) in Q2 2023.
Raises full-year VYVGART revenue guidance to exceed $80.0M; cash position $730.0M as of June 30.
Three NMPA product approvals: XACDURO (HABP/VABP), efgartigimod SC (gMG), AUGTYRO (ROS1+ NSCLC).
Expanded global oncology pipeline with next-gen ROR1 ADC (ZL-6301) via MabCare partnership.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.